Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxepin versus duloxetine for chemotherapy-induced peripheral neuropathy
IRCT20240721062502N2Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of doxepin and duloxetine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Shiraz University of Medical Sciences. Started Jan 2025; status: completed.
02
Drugs
doxepinduloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20240721062502N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240721062502N2.